U.S. markets closed
  • S&P Futures

    3,836.25
    +27.00 (+0.71%)
     
  • Dow Futures

    31,107.00
    +195.00 (+0.63%)
     
  • Nasdaq Futures

    13,008.00
    +97.00 (+0.75%)
     
  • Russell 2000 Futures

    2,232.10
    +32.90 (+1.50%)
     
  • Crude Oil

    62.51
    +1.01 (+1.64%)
     
  • Gold

    1,737.50
    +8.70 (+0.50%)
     
  • Silver

    26.83
    +0.39 (+1.46%)
     
  • EUR/USD

    1.2093
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3977
    +0.0055 (+0.40%)
     
  • USD/JPY

    106.4760
    -0.0260 (-0.02%)
     
  • BTC-USD

    45,552.69
    -165.47 (-0.36%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    0.00 (0.00%)
     

Lilly's diabetes drug as effective as Sanofi's in late-stage trials

May 12 (Reuters) - Eli Lilly and Co said its type 2 diabetes treatment was as effective as Sanofi SA's approved drug Lantus in reducing patients' blood sugar levels in three late-stage trials.

Lilly said it expected to file for European and U.S. regulatory approval of the drug, called basal insulin peglispro, by the end of first quarter of 2015.

(Reporting by Esha Dey in Bangalore; Editing by Savio D'Souza)